Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and the Obesity Society

González-Campoy, J. Michael; Castorino, Kristin; Ebrahim, Ayesha; Hurley, Dan; Jovanovič, Lois; Mechanick, Jeffrey I.; Petak, Steven M.; Yu, Yi-Hao; Jeor, Sachiko T. St.; Harris, Kristina A.; Kris-Etherton, Penny M.; Kushner, Robert F.; Molini-Blandford, Maureen; Nguyen, Quang T.; Plodkowski, Raymond A.; Sarwer, David B.; Thomas, Karmella T.; Bailey, Timothy S.; Bloomgarden, Zachary T.; Braverman, Lewis E.; Brett, Elise M.; Caldarella, Felice A.; Camacho, Pauline M.; Cheskin, Lawrence J.; Dagogo-Jack, Sam; Dodell, Gregory; Einhorn, Daniel; Garber, Alan J.; Garvey, Timothy; Gharib, Hossein; Grunberger, George; Haas, Richard; Handelsman, Yehuda; Harrell, R. Mack; Lando, Howard M.; Levine, Martin D.; Licata, Angelo A.; McGill, Janet B.; McMahon, M. Molly; Pearce, Elizabeth; Pessah-Pollack, Rachel; Rettinger, Herbert I.; Ryan, Donna H.; Shambaugh, George E.; Tangpricha, Vin; Thomas, Asha; Torre, J. L. Palancar de la; Weber, Sandra; Weiß, Daniel

doi:10.4158/ep13155.gl

Cited by 98 publications

(100 citation statements)

References 614 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although bariatric surgery may result in greater weight loss than other obesity interventions, it is an invasive procedure that requires important long-term commitment and follow-up by patients and health-care teams. Consequently, current treatment recommendations reserve bariatric surgery for people with BMI ≥ 40 or ≥ 35 with obesity-associated complications [120,[126][127][128][133][134][135] . Those who are interested in further updating their knowledge on current alternatives for obesity treatment will find a recent review to be a great help [121,136] .…”

Section: Traditional Approachmentioning

confidence: 99%

White Adipose Tissue and Circadian Rhythm Dysfunctions in Obesity: Pathogenesis and Available Therapies

2016

View full text Add to dashboard Cite

A combined neuroendocrine, metabolic, and chronobiological view can help to better understand the multiple and complex mechanisms involved in obesity development and maintenance, as well as to provide new effective approaches for its control and treatment. Indeed, we have currently updated data on the whole adipogenic process involved in white adipose tissue (WAT) mass expansion, namely due to a mechanism whereby WAT cells become hypertrophic, thus inducing a serious local (WAT) inflammatory condition that in turn, will impair not only the cross-talk between the hypothalamus and the WAT, but also favoring the development of deep and widespread neuroendocrine-metabolic dysfunction. Moreover, we also have revisited the circadian clock genes involved in dysfunctional WAT mass expansion and the mechanisms that may lead to obesity development, including early metabolic dysfunctions, enhanced oxidative stress and distorted energy homeostasis. The epigenetic changes of clock genes driving metabolic disease and obesity development have also been included in this review. Finally, we have also underlined the relevance of metabolic homeostasis regulation by central and peripheral organ clocks, sleep disturbances, nutrients, and feeding time, as key factors in obesity development as well as both, classical and chronotherapeutic approaches for its prevention and treatment.

show abstract

Section: Traditional Approachmentioning

confidence: 99%

White Adipose Tissue and Circadian Rhythm Dysfunctions in Obesity: Pathogenesis and Available Therapies

2016

View full text Add to dashboard Cite

show abstract

“…The most recent clinical practice recommendations from the American Diabetes Association recommend DPP-4 inhibitors as an option for second-line addition to metformin and as a component of three-drug combinations with a variety of antihyperglycemic agents 1. Likewise, the 2013 American Association of Clinical Endocrinologists’ consensus statement noted DPP-4 inhibitors as having possible benefits when used as monotherapy or as a component of dual or triple therapy 2. DPP-4 inhibitors are noted as having a low risk of hypoglycemia, a weight-neutral profile, and favorable tolerability when compared with other pharmacological agents for the treatment of T2DM.…”

Section: Discussionmentioning

confidence: 99%

“…Dipeptidyl peptidase-4 (DPP-4) inhibitors are one such class of agents that provide clinicians with a novel mechanism of action to utilize, often in combination with other therapies, for the treatment of T2DM. In fact, current clinical recommendations and guidelines advocate for the use of combination therapy approaches taking advantage of different, yet complementary, mechanisms of action to achieve glycemic goals 1,2. While alogliptin has been studied in a variety of combination studies including, but not limited to, as add-on to glyburide3 and insulin,4 this article will focus on clinical data pertaining to alogliptin used as monotherapy and as combination therapy with metformin and pioglitazone.…”

Section: Introductionmentioning

confidence: 99%

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Holland¹,

Neumiller²

2014

DMSO

View full text Add to dashboard Cite

Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenience in addition to an effective mode of delivering combination therapy to improve glycemic control. Alogliptin has been studied clinically as initial therapy in treatment-naïve patients with T2DM and as initial therapy or add-on in combination with other antidiabetic agents. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of glycosylated hemoglobin A1c and fasting plasma glucose reductions when used both as monotherapy and as a component of two- or three-drug combination regimens for the treatment of T2DM. Extensive Phase II and Phase III clinical trial data support the use of alogliptin in combination with metformin and pioglitazone. Glycemic reduction with both combinations is similar to the sum of the respective monotherapies, with adverse event rates similar – or more moderate – than those observed with up-titration of monotherapy or the addition of other antihyperglycemic agents.

show abstract

“…Именно нейрогуморальные фак-торы локальных висцеральных жировых депо явля-ются главными участниками патогенеза системных и органных нарушений [2,3], которые обычно опи-сываются как компоненты метаболического син-дрома (МС). Стало понятно, что различные сочета-ния метаболически нейтрального подкожного ожи-рения и метаболически агрессивного висцерального ожирения (ВО) могут привести к формированию раз-личных метаболических фенотипов ожирения, кото-рые отличаются по степени риска кардиометаболиче-ских осложнений [4].…”

Section: в помощь практическому врачуunclassified

Methods of Visceral Obesity Assessment in Clinical Practice

Чумакова¹,

Веселовская²

2016

Russ J Cardiol

View full text Add to dashboard Cite

Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and the Obesity Society

Cited by 98 publications

References 614 publications

White Adipose Tissue and Circadian Rhythm Dysfunctions in Obesity: Pathogenesis and Available Therapies

White Adipose Tissue and Circadian Rhythm Dysfunctions in Obesity: Pathogenesis and Available Therapies

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Methods of Visceral Obesity Assessment in Clinical Practice

Contact Info

Product

Resources

About